Proteome profiling to advance management of metabolic dysfunction-associated fatty liver disease

被引：0
|
作者：
Eslam, Mohammed [1 ,2 ]
Mendez-Sanchez, Nahum [3 ]
Zheng, Ming-Hua [4 ,5 ,6 ]
机构：
[1] Westmead Hosp, Westmead Inst Med Res, Storr Liver Ctr, 176 Hawkesbury Rd, Sydney, NSW 2145, Australia
[2] Univ Sydney, 176 Hawkesbury Rd, Sydney, NSW 2145, Australia
[3] Med Clin Fdn, Liver Res Unit, Mexico City, DF, Mexico
[4] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatol, NAFLD Res Ctr, Wenzhou, Peoples R China
[5] Wenzhou Med Univ, Inst Hepatol, Wenzhou, Peoples R China
[6] Key Lab Diag & Treatment Dev Chron Liver Dis Zhej, Wenzhou, Peoples R China
来源：
HEPATOBILIARY SURGERY AND NUTRITION | 2024年 / 13卷 / 01期
基金：
英国医学研究理事会;
关键词：
Metabolic dysfunction-associated fatty liver disease (MAFLD); fatty liver disease (FLD); fibrosis; proteome; biomarkers;
D O I：
10.21037/hbsn-23-596
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：147 / 149
页数：3
相关论文
共 50 条
  • [41] Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
    Gao, Zhifeng
    Deng, Huan
    Qin, Bowen
    Bai, Liang
    Li, Jiangwei
    Zhang, Jian
    FRONTIERS IN MEDICINE, 2025, 12
  • [42] Role of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease
    He, Qiongyao
    He, Wu
    Dong, Hui
    Guo, Yujin
    Yuan, Gang
    Shi, Xiaoli
    Wang, Dingkun
    Lu, Fuer
    CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
  • [43] The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease
    Martin-Mateos, Rosa
    Albillos, Agustin
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [44] Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China
    Liao, Shenling
    An, Kang
    Liu, Zhi
    He, He
    An, Zhenmei
    Su, Qiaoli
    Li, Shuangqing
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (09)
  • [45] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [46] Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease
    Tamaki, Nobuharu
    Kurosaki, Masayuki
    Higuchi, Mayu
    Izumi, Namiki
    HEPATOLOGY RESEARCH, 2021, 51 (11) : 1172 - 1173
  • [47] Risk scores for metabolic dysfunction-associated fatty liver disease in pediatric obesity
    Lischka, Julia
    Lieb, Katharina
    Schanzer, Andrea
    Hojreh, Azadeh
    Ba-Ssalamah, Ahmed
    de Gier, Charlotte
    Walleczek, Nina-Katharina
    Zeyda, Maximilian
    Greber-Platzer, Susanne
    ANNALS OF NUTRITION AND METABOLISM, 2022, 78 (05) : 247 - 254
  • [48] Transcription factors, metabolic dysfunction-associated fatty liver disease, and therapeutic implications
    Hu, Shuwei
    Ai, Yingjie
    Hu, Chencheng
    Bawa, Fathima N. Cassim
    Xu, Yanyong
    GENES & DISEASES, 2025, 12 (03)
  • [49] Metabolic Dysfunction-Associated Fatty Liver Disease, Statins, and Atherosclerotic Cardiovascular Disease Reply
    Yeoh, Aaron
    Cheung, Ramsey
    Ahmed, Aijaz
    Chitnis, Amit S.
    Do, Albert
    Wong, Robert J.
    AMERICAN JOURNAL OF MEDICINE, 2024, 137 (01): : E15 - E15
  • [50] Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis
    Wen, Wen
    Li, Hong
    Wang, Chunyi
    Chen, Chen
    Tang, Jiake
    Zhou, Mengyun
    Hong, Xuwei
    Cheng, Yongran
    Wu, Qi
    Zhang, Xingwei
    Feng, Zhanhui
    Wang, Mingwei
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
12345